This filing details Twist Bioscience's stock surge following its mention by Anthropic as an 'independent evaluator' in an AI protein design campaign, which overshadowed a critical short report from Scorpion Capital. The short report argues the Anthropic collaboration is overhyped and financially insignificant, and that Anthropic's AI advancements pose a 'deflationary' threat to Twist's business model.
Twist Bioscience (TWST) shares experienced a significant surge, reaching a 52-week high, after Anthropic named them an 'independent evaluator' in an AI-driven protein design campaign. This positive market reaction occurred despite a critical short report from Scorpion Capital, which labeled Twist's AI drug-discovery narrative as a 'speculative delusion' and argued the Anthropic collaboration is not a strategic partnership but merely a contract for outsourced services. Scorpion Capital also highlighted that Anthropic's improved protein design accuracy could be 'deflationary' for Twist by reducing the need for physical constructs. The short-term implication is a strong bullish sentiment for TWST, overriding negative claims. The long-term implications depend on whether Twist can demonstrate a more substantial role in AI-driven drug discovery and if Scorpion Capital's 'deflationary' thesis proves accurate. The key opportunity for traders is the continued momentum if the market dismisses the short report, while the risk lies in the potential validity of Scorpion Capital's claims regarding the financial insignificance and deflationary threat.